Neuren Pharmaceuticals Ltd. is an Australian biopharmaceutical company focusing on developing innovative therapies for brain injury and neurodevelopment disorders. With a Risk Rating Score of 34.1, the company is considered high risk. Neuren Pharmaceuticals' drugs target symptoms of acute traumatic brain injury, Rett syndrome, and Fragile X syndrome. The company operates in two main segments: Commercial Products and Research and Development, generating the majority of its revenue from Commercial Products. Improve your ESG score with Neuren Pharmaceuticals Ltd.'s groundbreaking pharmaceutical solutions.